Contingency Management in the Delivery of HAART to Drug Users in Chennai, India

Study Overview
=================
Brief Summary
-----------------
Drug use (DU) is a major risk factor for HIV infection in many regions of the world. However, as highly active antiretroviral therapy (HAART) has been rolled out in South and South East Asia, less than 2% of individuals initiated on HAART were drug users (DUs) or former DUs, despite the fact that approximately 20% of HIV infections in the region are ascribed to DU. India is home to about 2.4 million HIV-infected individuals. Though, injection drug users contribute to only about 3% of all HIV infections in India; it is estimated that there are between 168,000 and 1.1 million DUs in India with HIV prevalence about 30%. Novel approaches are needed to engage disenfranchised populations in HIV care in lower and middle income countries, where the burden of HIV disease is growing. Incentive-based strategies (or contingency management) have been shown to be effective in reducing illicit drug use, smoking cessation, and weight loss. Short-term pilot studies have also shown that incentive-based strategies can improve electronically-monitored rates of adherence to HAART in the US, and a recent study in Africa showed that a small incentive approximately doubled the rate that individuals returned to learn the results of their HIV test. However, to date there is no experience with the use of incentive-based interventions to improve engagement into care and risk-reduction among out-of-care HIV-infected DUs in developing world settings. The investigators propose to conduct pilot randomized trial comparing a voucher incentive strategy to a control condition to improve engagement in HIV care and HIV treatment outcomes among out-of-care, treatment-eligible, HIV-infected DUs in Chennai, India. Subjects in the incentive arm will be eligible to earn incentive vouchers for 1) initiating HAART at a government-sanctioned HIV treatment clinic, 2) adherence to scheduled follow-up visits at the HIV clinic, and 3) achieving suppression of HIV RNA. Subjects will be enrolled from a mature research venue in Chennai, YR Gaitonde Centre for Substance Abuse-related Research (YRGCSAR), which focuses the epidemiology and natural history of HIV in DUs. Preliminary data from this pilot study will be used to inform the design of a phase-III study.

Conditions
-----------------
HIV, Substance Abuse, Intravenous

Intervention / Treatment
-----------------
* Behavioral: Contingency
* Other: Prize bowl drawings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Provide written informed consent Provide a history of injection or non-injection drug use in prior 30 days Documented evidence of HIV infection Be ART naïve (by self-report) Satisfy Indian National Guidelines for initiation of HAART (any of the following) Absolute CD4+ count < 200 cells/ µl AIDS-defining illness with any CD4+ count Absolute CD4+ count between 200 - 350 cell/ µl with HIV-related symptoms Exclusion Criteria: Indicates an intention to migrate in the next 12 months Any medical or psychiatric condition that the study physician believes to be a contraindication to study participation. Enrolled in another HIV treatment program

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Contingency<br> | Behavioral: Contingency<br>* Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA<br>|
| Active Comparator: Control<br> | Other: Prize bowl drawings<br>* Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to initiation of HAART |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attendance at HIV treatment visits |  | 12-months | 
| HAART possession ratio (a surrogate of medication adherence based on pharmacy fill data) |  | 12-months | 
| Proportion with HIV RNA < 400 copies/mL at 6- and 12-months |  | 12-month | 
| Changes in absolute CD4 count from baseline at 6- and 12-months |  | 12-months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Complementary Therapies, Drug Users